Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments (CDC-RFA-PS21-2103)
Tools exist to prevent new cases of hepatitis A, hepatitis B, and hepatitis C, to treat people living with hepatitis B, and to cure people living with hepatitis C. Yet new cases of viral hepatitis continue to rise, many people infected with viral hepatitis remain undiagnosed, and far too many viral hepatitis-related deaths occur in the United States each year. This cooperative agreement supports integrated viral hepatitis surveillance and prevention programs in states, territories, and large cities in the United States over five years (2021–2026). It will support the capacity of states, territories, and large cities to detect and respond to viral hepatitis outbreaks; to collect and analyze data to inform the development and implementation of public health interventions to prevent and control viral hepatitis; and to support viral hepatitis elimination planning and maximize access to viral hepatitis prevention, testing, and treatment to reduce the burden of viral hepatitis in their jurisdictions.
Key strategies include:
Component 1: Core Viral Hepatitis Outbreak Response and Surveillance Activities
- 1.1: Develop, implement, and maintain a plan to rapidly detect and respond to outbreaks of hepatitis A, hepatitis B, and hepatitis C
- 1.2: Systematically collect, analyze, interpret, and disseminate data to characterize trends and implement public health interventions for hepatitis A, acute hepatitis B, and acute and chronic hepatitis C
- 1.3 (contingent on available funding): Systematically collect, analyze, interpret, and disseminate data to characterize trends and implement public health interventions for chronic hepatitis B and perinatal hepatitis C
Component 2: Core Viral Hepatitis Prevention Activities
- 2.1: Support viral hepatitis elimination planning and surveillance and maximize access to testing, treatment, and prevention
- 2.2 (contingent on available funding): Increase access to hepatitis C and hepatitis B testing and referral to care in high-impact settings
- 2.3 (contingent on available funding): Improve access to services preventing viral hepatitis among people who inject drugs
Component 3: Special Projects—Prevention, Diagnosis, and Treatment Related to the Infectious Disease Consequences of Drug Use
- 3.1: Improve access to services for people who inject drugs in settings disproportionately affected by drug use
- 3.2 (contingent on available funding): Implement prevention services and interventions to address emerging issues related to drug use
Expected outcomes include improved surveillance for viral hepatitis, increased stakeholder engagement in viral hepatitis elimination planning, and improved access to viral hepatitis prevention, diagnosis, and treatment among populations most at risk.